News & Updates
Filter by Specialty:
Ongoing anticancer treatment dulls immune response against COVID-19
Therapy-naïve patients with haematological malignancies are able to mount a stronger immune response to the coronavirus disease 2019 (COVID-19), a recent study has found.
Ongoing anticancer treatment dulls immune response against COVID-19
19 Feb 2022Lipoprotein(a) molar concentrations help inform cardiovascular risk
The risk of coronary artery disease (CAD) can be predicted by a single accurate measurement of lipoprotein(a) molar concentration if therapies substantially altering lipoprotein(a) are not present, suggests a recent study.
Lipoprotein(a) molar concentrations help inform cardiovascular risk
19 Feb 2022Lower SLERPI cutoff improves early diagnosis in SLE patients with fever, thrombosis
Hospitalization is warranted in one in five patients with new-onset systemic lupus erythematosus (SLE) manifest disease presentations, according to a recent study. Of note, diagnosis has been delayed in nearly 20 percent of patients.
Lower SLERPI cutoff improves early diagnosis in SLE patients with fever, thrombosis
19 Feb 2022Edoxaban effectively keeps D-dimer low in patients with NVAF, AHF
Patients with nonvalvular atrial fibrillation (NVAF) and acute heart failure (AHF) see elevated levels of D-dimer, for which edoxaban may be effective, reports a recent study.
Edoxaban effectively keeps D-dimer low in patients with NVAF, AHF
19 Feb 2022Genetically elevated FT4 levels tied to higher age-related macular degeneration risk
Patients who have genetically elevated free thyroxine (FT4) levels are at heightened risk of age-related macular degeneration, according to the results of a Mendelian randomization study.
Genetically elevated FT4 levels tied to higher age-related macular degeneration risk
19 Feb 2022Stroke risk elevated first 3 days post–COVID-19 diagnosis
Older patients with COVID-19 may have an increased risk of being hospitalized for acute ischaemic stroke (AIS), particularly in the first 3 days following their COVID-19 diagnosis, according to a study presented at ISC 2022.
Stroke risk elevated first 3 days post–COVID-19 diagnosis
18 Feb 2022Ixazomib dexamethasone a new treatment in the arsenal against RRMM
In heavily pretreated, lenalidomide-refractory patients with relapsed-refractory multiple myeloma (RRMM) and prior exposure to proteasome inhibitors, ixazomib dexamethasone may be an effective and tolerable treatment approach, leading to comparable health-related quality of life outcomes as pomalidomide-dexamethasone, a recent study has found.